Media Coverage

KindredBio becomes commercial entity as Mirataz goes on sale


Jul 09, 2018 - Animal Pharm
By Joseph Harvey
Animal Pharm
July 9, 2018


US pet therapeutics company Kindred Biosciences has become a commercial entity around six years after it was founded.

The firm's Mirataz (mirtazapine transdermal ointment) is now available to veterinarians in the US after it secured FDA approval earlier this year. The product is the first FDA-authorized transdermal medication for the management of weight loss in cats.

Last month, KindredBio detailed its salesforce strategy for Mirataz and its upcoming product approvals. The Californian company has been revving up its commercial engine over recent quarters in anticipation of its debut product launch.

Early signs of Mirataz's sales performance will be published in August, when KindredBio will announce its second-quarter results. In Q1, the company's net loss reached around $10 million.

KindredBio said: "Unintended weight loss in cats is a serious and potentially fatal condition that represents the leading cause of visits to the veterinarian for cats. Mirataz is a serotonin and histamine receptor antagonist, which has demonstrated body weight gain in cats experiencing weight loss.

"The product is classified as a weight gain drug and can be used in cats experiencing unintended weight loss caused by varying underlying conditions. Formulated with KindredBio's proprietary Accusorb technology, Mirataz is applied topically to the cat's inner ear once a day, providing an attractive application route instead of oral dosing."

The company claims there are around nine million cats experiencing unintended weight loss due to underlying conditions annually in the US.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum